Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL-Reference-Cited by-同舟云学术

Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL

Published:2022-10-23 Issue:1 Volume:110 Page:99-108
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Benjamini Ohad¹²,Gershon Rotem²,Bar‐Haim Erez³^ORCID,Lustig Yaniv⁴,Cohen Hila³,Doolman Ram⁵,Kedmi Meirav¹²⁶,Ribakovsky Elena¹,Kneller Abraham¹,Hod Tammy²⁷^ORCID,Erez Noam⁸,Levy Itzhak²⁹,Rahav Galia²⁹,Avigdor Abraham¹²

Affiliation:

1. Hematology Division Chaim Sheba Medical Centre Tel‐Hashomer Israel

2. Sackler Faculty of Medicine Tel‐Aviv University Tel Aviv Israel

3. Department of Biochemistry and Molecular Genetics Israel Institute for Biological Research Ness‐Ziona Israel

4. Central Virology Laboratory Ministry of Health and Chaim Sheba Medical Center Tel‐Hashomer Israel

5. The Dworman Automated‐Mega Laboratory Sheba Medical Center Tel‐Hashomer Israel

6. The Mina and Everard Goodman Faculty of Life Science Bar‐Ilan University Ramat‐Gan Israel

7. Nephrology Department Chaim Sheba Medical Centre Tel‐Hashomer Israel

8. Department of Infectious Diseases Israel Institute for Biological Research Ness‐Ziona Israel

9. The Infectious Disease Unit Chaim Sheba Medical Center Tel‐Hashomer Israel

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13878

Reference34 articles.

1. https://coronavirus.jhu.edu/map.html.2022.

2. BNT162b2 mRNA COVID‐19 vaccine in a nationwide mass vaccination setting. Reply;Barda N;N Engl J Med,2021

3. Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel

4. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

5. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia;Acta Haematologica;2024-03-12

2. In silico clinical studies for optimal COVID-19 vaccination schedules in patients with cancer;Cell Reports Medicine;2024-03

3. Sequential cellular and humoral responses after repetitive COVID‐19 vaccination in patients treated with anti‐CD20 antibodies;British Journal of Haematology;2023-11-14

4. COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?;Acta Haematologica;2023-10-11

5. Prevalencia de anticuerpos contra SARS-CoV-2 en pacientes con cáncer y trabajadores de la salud vacunados con dos dosis de BNT162b2 o AZD122. Análisis de propensión;Gaceta Médica de México;2023-09-21